1
|
Abstract
Precision (P4) medicine represents a new medical paradigm that focuses on Personalized, Predictive, Preventive and Participatory approaches. The P4 paradigm is particularly appropriate for moving the care of persons with myopenia forward. Muscular dystrophies are clearly a set of genetically different diseases where genomics are the basis of diagnosis, and genetic modulation via DNA, oligonucleotides and clustered regularly interspaced short palendronic repeats hold great potential for a cure. The utility of personalized genomics for sarcopenia coupled with utilizing a predictive approach for the diagnosis with early preventive strategies is a key to improving sarcopenic outcomes. The importance of understanding different levels of patient enthusiasm and different responses to exercise should guide the participatory phase of sarcopenic treatment. In the case of cachexia, understanding the effects of the different therapies now available through the P4 approach on muscle wasting is a key to management strategies.
Collapse
Affiliation(s)
- John E. Morley
- Division of Geriatric MedicineSaint Louis University School of Medicine1402 S. Grand Blvd., M238St. LouisMO63104USA
| | - Stefan D. Anker
- Division of Innovative Clinical Trials, Department of Cardiology and PneumologyUniversity Medical Centre GöttingenRobert‐Koch‐Straße 40, D‐37075GöttingenGermany
| |
Collapse
|
2
|
Seitter H, Koschak A. Relevance of tissue specific subunit expression in channelopathies. Neuropharmacology 2017; 132:58-70. [PMID: 28669898 DOI: 10.1016/j.neuropharm.2017.06.029] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 06/22/2017] [Accepted: 06/28/2017] [Indexed: 12/27/2022]
Abstract
Channelopathies are a diverse group of human disorders that are caused by mutations in genes coding for ion channels or channel-regulating proteins. Several dozen channelopathies have been identified that involve both non-excitable cells as well as electrically active tissues like brain, skeletal and smooth muscle or the heart. In this review, we start out from the general question which ion channel genes are expressed tissue-selectively. We mined the human gene expression database Human Protein Atlas (HPA) for tissue-enriched ion channel genes and found 85 genes belonging to the ion channel families. Most of these genes were enriched in brain, testis and muscle and a complete list of the enriched ion channel genes is provided. We further focused on the tissue distribution of voltage-gated calcium channel (VGCC) genes including different brain areas and the retina based on the human gene expression from the FANTOM5 dataset. The expression data is complemented by an overview of the tissue-dependent aspects of L-type calcium channel (LTCC) function, dysfunction and pharmacology, as well as of their splice variants. Finally, we focus on the pathology of tissue-restricted LTCC channelopathies and their treatment options. This article is part of the Special Issue entitled 'Channelopathies.'
Collapse
Affiliation(s)
- Hartwig Seitter
- University of Innsbruck, Institute of Pharmacy, Pharmacology and Toxicology, Center for Chemistry and Biomedicine, Innrain 80-82/III, 6020 Innsbruck, Austria
| | - Alexandra Koschak
- University of Innsbruck, Institute of Pharmacy, Pharmacology and Toxicology, Center for Chemistry and Biomedicine, Innrain 80-82/III, 6020 Innsbruck, Austria.
| |
Collapse
|
3
|
Germini D, Bou Saada Y, Tsfasman T, Osina K, Robin C, Lomov N, Rubtsov M, Sjakste N, Lipinski M, Vassetzky Y. A One-Step PCR-Based Assay to Evaluate the Efficiency and Precision of Genomic DNA-Editing Tools. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT 2017; 5:43-50. [PMID: 28480303 PMCID: PMC5415314 DOI: 10.1016/j.omtm.2017.03.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 03/03/2017] [Indexed: 12/16/2022]
Abstract
Despite rapid progress, many problems and limitations persist and limit the applicability of gene-editing techniques. Making use of meganucleases, TALENs, or CRISPR/Cas9-based tools requires an initial step of pre-screening to determine the efficiency and specificity of the designed tools. This step remains time consuming and material consuming. Here we propose a simple, cheap, reliable, time-saving, and highly sensitive method to evaluate a given gene-editing tool based on its capacity to induce chromosomal translocations when combined with a reference engineered nuclease. In the proposed technique, designated engineered nuclease-induced translocations (ENIT), a plasmid coding for the DNA-editing tool to be tested is co-transfected into carefully chosen target cells along with that for an engineered nuclease of known specificity and efficiency. If the new enzyme efficiently cuts within the desired region, then specific chromosomal translocations will be generated between the two targeted genomic regions and be readily detectable by a one-step PCR or qPCR assay. The PCR product thus obtained can be directly sequenced, thereby determining the exact position of the double-strand breaks induced by the gene-editing tools. As a proof of concept, ENIT was successfully tested in different cell types and with different meganucleases, TALENs, and CRISPR/Cas9-based editing tools.
Collapse
Affiliation(s)
- Diego Germini
- UMR8126, Université Paris Sud - Paris Saclay, CNRS, Institut Gustave Roussy, 94805 Villejuif, France.,LIA 1066, French-Russian Joint Cancer Research Laboratory, 94805 Villejuif, France.,Department of Biophysics, Institute of Physics, Nanotechnology, and Telecommunications, Peter the Great St. Petersburg Polytechnic University, St. Petersburg 195251, Russia
| | - Yara Bou Saada
- UMR8126, Université Paris Sud - Paris Saclay, CNRS, Institut Gustave Roussy, 94805 Villejuif, France.,LIA 1066, French-Russian Joint Cancer Research Laboratory, 94805 Villejuif, France
| | - Tatiana Tsfasman
- UMR8126, Université Paris Sud - Paris Saclay, CNRS, Institut Gustave Roussy, 94805 Villejuif, France.,LIA 1066, French-Russian Joint Cancer Research Laboratory, 94805 Villejuif, France
| | - Kristina Osina
- UMR8126, Université Paris Sud - Paris Saclay, CNRS, Institut Gustave Roussy, 94805 Villejuif, France.,University of Latvia, 1586 Riga, Latvia
| | - Chloé Robin
- UMR8126, Université Paris Sud - Paris Saclay, CNRS, Institut Gustave Roussy, 94805 Villejuif, France
| | - Nikolay Lomov
- UMR8126, Université Paris Sud - Paris Saclay, CNRS, Institut Gustave Roussy, 94805 Villejuif, France.,LIA 1066, French-Russian Joint Cancer Research Laboratory, 94805 Villejuif, France.,M.V. Lomonosov Moscow State University, Moscow 119991, Russia
| | - Mikhail Rubtsov
- LIA 1066, French-Russian Joint Cancer Research Laboratory, 94805 Villejuif, France.,M.V. Lomonosov Moscow State University, Moscow 119991, Russia.,Department of Biochemistry and Strategic Management Department, I.M. Sechenov First Moscow State Medical University, Moscow 119048, Russia
| | | | - Mar Lipinski
- UMR8126, Université Paris Sud - Paris Saclay, CNRS, Institut Gustave Roussy, 94805 Villejuif, France.,LIA 1066, French-Russian Joint Cancer Research Laboratory, 94805 Villejuif, France
| | - Yegor Vassetzky
- UMR8126, Université Paris Sud - Paris Saclay, CNRS, Institut Gustave Roussy, 94805 Villejuif, France.,LIA 1066, French-Russian Joint Cancer Research Laboratory, 94805 Villejuif, France.,M.V. Lomonosov Moscow State University, Moscow 119991, Russia
| |
Collapse
|
4
|
Artilheiro MC, Cardoso de Sá CDS, Fávero FM, Wutzki HC, de Resende MBD, Caromano FA, Voos MC. Hand Function in Muscular Dystrophies. Percept Mot Skills 2017; 124:441-451. [DOI: 10.1177/0031512516688834] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The aim of this study was to investigate the relationship between Performance of Upper Limb (PUL) and Jebsen–Taylor Test (JTT) to assess and monitor upper limb function progression in patients with muscular dystrophy. Thirty patients diagnosed with Duchenne muscular dystrophy, limb-girdle muscular dystrophy, Becker muscular dystrophy, myotonic dystrophy Type 1, and fascioscapulohumeral dystrophy were submitted to the shoulder, elbow, and wrist domains of PUL, and to JTT subtests. Spearman tests investigated the relationships between PUL and JTT total scores and domains. Correlations were classified as strong ( r ≥ 0.70), moderate (0.40 ≤ r < 0.70), or weak ( r ≤ 0.40). There were strong correlations between the PUL and JTT total scores ( r = −0.706). Although JTT measures time and PUL provides kinesiologic scores, these measures were related. Therefore, muscle synergies, which control the compensatory movements and motor functions involving mainly shoulder, elbow, wrist, and finger movements, are related to timed performance in patients with muscular dystrophies.
Collapse
Affiliation(s)
| | | | - Francis M. Fávero
- Department of Neurology or Neurosurgery, Federal University of São Paulo, Brazil
| | | | | | | | | |
Collapse
|
5
|
Zamyatnin AA. Special Issue: Genome Editing and Gene Therapy. BIOCHEMISTRY (MOSCOW) 2017; 81:651-2. [PMID: 27449611 DOI: 10.1134/s0006297916070014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Gene therapy is one of the most rapidly developing fields of molecular medicine. Gene therapy allows simple transfer of genetic methods aimed at correcting pathological processes into clinical practice. However, a number of technical problems still exists limiting broad use of gene therapy approaches. This special issue discusses modern methods and approaches used for the development of novel, effective, and safe agents for gene therapy.
Collapse
Affiliation(s)
- A A Zamyatnin
- Sechenov First Moscow State Medical University, Institute of Molecular Medicine, Moscow, 119991, Russia.
| |
Collapse
|